{"organizations": [], "uuid": "f635ce6fc751860e807b7d047a8a9ce030dc7227", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180404.html", "section_title": "Archive News &amp; Video for Wednesday, 04 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-resul/brief-tenax-therapeutics-announces-results-of-pre-ind-meeting-with-fda-for-phase-2-study-of-levosimendan-idUSFWN1RH05B", "country": "US", "domain_rank": 408, "title": "BRIEF-Tenax Therapeutics Announces Results Of Pre-Ind Meeting With FDA For Phase 2 Study Of Levosimendan", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.62, "site_type": "news", "published": "2018-04-04T20:07:00.000+03:00", "replies_count": 0, "uuid": "f635ce6fc751860e807b7d047a8a9ce030dc7227"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-resul/brief-tenax-therapeutics-announces-results-of-pre-ind-meeting-with-fda-for-phase-2-study-of-levosimendan-idUSFWN1RH05B", "ord_in_thread": 0, "title": "BRIEF-Tenax Therapeutics Announces Results Of Pre-Ind Meeting With FDA For Phase 2 Study Of Levosimendan", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "tenax therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Tenax Therapeutics Inc:\n* TENAX THERAPEUTICS ANNOUNCES RESULTS OF PRE-IND MEETING WITH FDA FOR PHASE 2 STUDY OF LEVOSIMENDAN IN PH HFPEF PATIENTS\n* FDA AGREED THAT NEW PHASE 2 CLINICAL PROTOCOL CAN BE SUBMITTED UNDER EXISTING IND\n* HFPEF PATIENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-04T20:07:00.000+03:00", "crawled": "2018-04-05T17:25:56.024+03:00", "highlightTitle": ""}